Get the Stockscreener App
13.48
3.37%
0.44
Pre-market:
13.48
Arcutis Biotherapeutics Inc stock is traded at $13.48, with a volume of 1.89M.
It is up +3.37% in the last 24 hours and down -11.55% over the past month.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$13.04
Open:
$13.12
24h Volume:
1.89M
Relative Volume:
0.83
Market Cap:
$1.61B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-3.4388
EPS:
-3.92
Net Cash Flow:
$-247.49M
1W Performance:
-3.58%
1M Performance:
-11.55%
6M Performance:
+8.58%
1Y Performance:
+61.24%
1-Day Range:
$13.12
$13.65
1-Week Range:
$12.83
$14.30
52-Week Range:
$6.99
$17.75
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
13.48 | 1.69B | 59.61M | -262.14M | -247.49M | -3.92 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Transcript : Arcutis Biotherapeutics, Inc.Shareholder/Analyst Call - marketscreener.com
Possible Bearish Signals With Arcutis Biotherapeutics Insiders Disposing Stock - simplywall.st
Arcutis Biotherapeutics SVP sells $24,806 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics SVP sells $24,806 in stock - Investing.com Australia
Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Immuno-Dermatology Leader Arcutis Set for Key Goldman Sachs Healthcare Conference Presentation - Stock Titan
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by Bank of America Corp DE - Defense World
Needham & Company LLC Reaffirms Buy Rating for Arcutis Biotherapeutics (NASDAQ:ARQT) - Defense World
Arcutis wins FDA nod for Zoryve foam for plaque psoriasis - MSN
Analyst Expectations For Arcutis Biotherapeutics's Future - Benzinga
ARQT Analyst Reiterates Buy Rating with $20 Price Target | ARQT Stock News - GuruFocus
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older - BioSpace
FDA approves roflumilast foam 0.3% for scalp, body psoriasis - Contemporary Pediatrics
FDA approves ZORYVE foam for plaque psoriasis treatment - Investing.com Australia
FDA Approves Arcutis' (ARQT) Zoryve Foam for Psoriasis Treatment - GuruFocus
Arcutis Biotherapeutics' Foam Psoriasis Treatment Gets FDA Approval - marketscreener.com
FDA Approval Boosts Arcutis Biotherapeutics (ARQT) with New Psor - GuruFocus
Arcutis wins FDA nod for Zoryve foam in psoriasis (ARQT:NASDAQ) - Seeking Alpha
Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older | ARQT Stock News - GuruFocus
FDA approves ZORYVE foam for plaque psoriasis treatment By Investing.com - Investing.com India
Understanding Roflumilast Foam's FDA Approval for Scalp and Body Psoriasis, with Jennifer Soung, MD - HCPLive
Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older - The Manila Times
Better Weight Loss Stock: Amgen or Viking Therapeutics? - The Globe and Mail
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
79,815 Shares in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Acquired by BNP Paribas Financial Markets - Defense World
The Manufacturers Life Insurance Company Sells 1,547 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
When the Price of (ARQT) Talks, People Listen - news.stocktradersdaily.com
ARQT: Key Insights from Genital Psoriasis Consensus Statements | - GuruFocus
New Consensus Statements on Impact of Genital Psoriasis on Patie - GuruFocus
Northern Trust Corp Acquires 54,541 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice - The Manila Times
Arcutis Biotherapeutics Publishes Expert Consensus on Genital Psoriasis to Enhance Patient Care and Treatment Decision-Making - Nasdaq
Medical Breakthrough: Experts Release 14 Game-Changing Guidelines for Genital Psoriasis Treatment - Stock Titan
Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy - openPR.com
Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics - Barchart.com
Director’s Bold Move: A Major Investment in Arcutis Biotherapeutics - TipRanks
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Hsbc Holdings PLC Increases Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and AMN Healthcare Services (AMN) - The Globe and Mail
Arcutis outlines growth potential with ZORYVE expansions and market penetration - MSN
Earnings Update: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
What is HC Wainwright’s Forecast for ARQT Q1 Earnings? - Defense World
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates - MSN
Arcutis Biotherapeutics: Zoryve foam treatment resulted in major improvements - Yahoo Finance
Arcutis Biotherapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2025 Earnings Call Transcript - Insider Monkey
Arcutis Biotherapeutics Reports Strong Q1 Earnings Growth - TipRanks
Jefferies lifts Arcutis stock target to $20 on strong sales By Investing.com - Investing.com South Africa
ZORYVE foam shows promise in psoriasis treatment By Investing.com - Investing.com South Africa
ZORYVE foam shows promise in psoriasis treatment - Investing.com
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):